Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0262471 (ENT)
 5,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The following conclusions emerged from an analysis of the therapeutic results documented during the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino)-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) in bacterial infections of the respiratory tract and ENT organs: 1. In bacterial infections of the bronchopulmonary system, the antibacterial activity of CN 3123 was demonstrated in 94% of the patients, in that 75% of patients were cured and there was a definite improvement in 19%. 2. In bacterial infections of the ENT organs, the antibacterial activity of CN 3123 was demonstrated clinically in 95% of the patients, in that 89% of the patients were cured and there was a definite improvement in 6%. 3. The clinical assessment of the activity of CN 3123 correlates closely with the results of bacteriological checks.
 ...
PMID:[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Third communication: Clinical results of a field trial with CN 3123 in bronchopulmonary and ENT (ear/nose/throat) infections (author's transl)]. 78 75

The antibacterial activity of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) was studied in various bacterial infections in the fields of internal medicine, dermatology and gynecology. It was found that: 1. CN 3123 exhibits antibacterial activity in bacterial infections of the intestinal tract, particularly in salmonellosis and shigellosis. 2. CN 3123 is effective against bacterial infections of the female genital organs. 3. CN 3123 is very effective in patients with bacterial infections of the skin. 4. The antibacterial activity of CN 3123 in these indications is comparable to its action on bacterial infections of the urinary organs and respiratory tract and in ENT infections.
 ...
PMID:[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Fourth communication: Clinical results with CN 3123 in infections of the gastrointestinal tract, the skin and gynecological adnexes (author's transl)]. 78 76